Neurogene Inc.’s NGNE share price has dipped by 18.34%, which has investors questioning if this is right time to buy.

Stock analysts at William Blair issued their Q1 2025 EPS estimates for Neurogene in a research report issued to clients and ...

Neurogene (NASDAQ: NGNE) stock just took a sharp dive, plummeting 44% in a single day. Bad news on Monday caused the pharmaceutical company's shares to drop massively in after-hours trading ...

EDT Neurogene (NGNE) files $300M mixed securities shelfLight Up your Portfolio with Spark:Easily identify stocks' risks and ...

Neurogene Inc. (NASDAQ:NGNE – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Neurogene in a report released on Monday, March 24th.

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and ...

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Neurogene (NGNE) to $50 from $55 and keeps a Buy rating on the ...

Neurogene Inc. announced its financial results for the fourth quarter and full year 2024, highlighting significant progress in its NGN-401 Phase 1/2 trial for Rett syndrome. The company remains on ...

Neurogene Inc. (NASDAQ:NGNE) is an important biotech to watch during this year, and it is because it is gearing up for two key catalysts that investors need to keep an eye on. The first of which ...

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and ...

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May ...

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and ...